Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research article

Dynamic changes in monocytes subsets in COVID-19 patients

Shuang Qin a,1, Yujie Jiang a,1, Xin Wei b, Xiaoyuan Liu c, Jingjing Guan a, Yingxiao Chen d, Hong Lu a, Jingjing Qian a, Zhongyong Wang a,⇑, Xiangyang Lin a,⇑

a Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
b Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China
c School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325000, China
d Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

Abstract

Background: Coronavirus disease 2019 (COVID-19) is affecting the whole world and threatening human health. We aim to investigate the immunological characteristics of monocytes in critical patients with COVID-19.

Methods: The number and immune status of monocytes were detected by flow cytometry in 32 COVID-19 patients and 18 healthy individuals.

Results: In critical patients with COVID-19, the absolute number of total monocytes and CD16+ monocytes was significantly decreased but CD16+ pro-inflammatory monocytes was increased compared to healthy controls. Antigen presentation potential of monocytes, as measured by HLA-DR expression, was suppressed, while their inflammatory phenotype (CD38 expression) was enhanced. Cytokine levels showed sustained increases in critical patients. And the levels of IL-6 were positively correlated with CD16+ monocytes number. IL-6 and IL-10 levels were negatively correlated with HLA-DR expression of monocytes. During the recovery of COVID-19 patients, the count and immune status of monocyte subsets were restored by degrees. HLA-DR+ monocytes possessed good sensitivity and specificity for predicting the incidence of critical patients with COVID-19.

Conclusions: In critical patients with COVID-19, decline in number and HLA-DR expression of monocytes might lead to decreased antigen presentation potential and thus immunosuppression, while increased CD16+ pro-inflammatory monocytes might mediate hyperinflammation. HLA-DR+ monocytes might be a meaningful assisted indicator to predict the incidence of critical patients with COVID-19.

© 2020 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.

1. Introduction

Coronavirus disease 2019 (COVID-19) is highly contagious, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The WHO declared its outbreak to be a global public health emergency [1]. Until October 15, 2020, 38,202,956 confirmed cases and 1,087,069 deaths were reported globally [2], far exceeding the total number of SARS cases in 2003. Among these COVID-19 patients, most of them had some common symptoms including fever, cough, myalgia or fatigue at the time of onset. Most patients with COVID-19 were mild and could recover after timely medical intervention. However, about 25% of patients would deteriorate into serious complications, including acute respiratory distress syndrome (ARDS), and even multiple organ failure and death [3,4]. Like many other infectious diseases, COVID-19 patients can be damaged by the pathogen or excessive immune response incited by the pathogen. However, the exact immune mechanisms causing damage remain unclear. Therefore, exploring the immune mechanism of COVID-19 patients is the focus of current research.

It is increasingly recognized that the innate immune system plays an important role in determining the clinical course of infection [5]. Monocytes are an essential part of the innate immune system. They can directly engulf pathogens or present antigens to T cells to produce cytokines, regulating both humoral and cellular immune responses [6–8]. Some studies had suggested a significant decrease of monocytes in COVID-19 patients with severe or critical disease [9,10]. However, the dynamic changes of monocytes in
critical patients with COVID-19 is still largely unclear. In this study, we focused on the immunological characteristics of monocytes in critical patients with COVID-19, monitored its dynamic changes in the number and immune status.

2. Materials and methods

2.1. Patients

Thirty-two COVID-19 patients in The First Affiliated Hospital of Wenzhou Medical University were recruited for this study. In the Guideline of the Diagnosis and Treatment of New Coronavirus Pneumonia (trial version 7) issued by the National Health Commission of China [11], the clinical classifications of COVID-19 are as follows: (1) Mild cases: The clinical symptoms were mild, and the imaging examination showed no signs of pneumonia. (2) Moderate cases: Showing fever and respiratory symptoms, accompanied by imaging manifestations of pneumonia. (3) Severe cases: Adult cases meet any of the following criteria: shortness of breath with respiratory rate ≥30 times/min, oxygen saturation ≤93% at rest, partial pressure of arterial oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kPa). (4) Critical cases: Cases meeting any of the following criteria: respiratory failure requires mechanical ventilation, shock or with other organ failures require ICU care; zai. According to the above classification criteria, all confirmed patients included 13 mild cases (merging the mild and moderate types defined in the guideline, male/female: 6/7; age: 59.69 ± 13.38), 10 severe cases (male/female: 7/3; age: 62.8 ± 13.03) and 9 critical cases (male/female: 6/3; age: 67.78 ± 17.22). There were no statistically significant differences in age and sex between groups. Within three days at admission, blood was collected before treatment for the different groups. And after admission for treatment, blood continued to be collected at intervals for the different groups to observe the trend of the number and function of cells and the therapeutic effect. All patients received standardized treatment in accordance with the above guidelines, including antiviral drugs such as α-interferon (α-IFN), ribavirin, lopinavir/ritonavir, etc., oxygen therapy, fluid management, antibiotics treatment if occasion required, symptomatic relief and supportive treatment. Eighteen healthy individuals with age and gender matching who were not infected with SARS-CoV-2 were used as healthy controls (HCs). The study protocol was approved by the ethics committee of The First Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from all subjects.

2.2. Laboratory examination

Specimens from patients included nasopharyngeal swab and blood samples. The presence of SARS-CoV-2 in nasopharyngeal swab was detected by real-time RT-PCR (rRT-PCR) assay. Serum cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ) were detected with human Th1/2 cytokine kit II and lymphocyte subsets were detected with BD Multitest IMK kit by BD FACSCanto II flow cytometer (BD Biosciences, California, USA). Monocytes subgroups (CD16−/CD16+ monocytes) were detected by Cytodiff. All tests were performed in accordance with the product manual.

2.3. Fluorescence-activated flow cytometry analysis

To detect the phenotypic and functional characteristics of monocytes, 100 μl of anti-coagulated fresh whole blood of confirmed COVID-19 patients was collected for fluorescence antibody staining. Cells were incubated with fluorescently labeled antibodies of 10 μl/test concentration for 15 min at room temperature. All samples were detected by the BD FACS Canto II flow cytometer and analyzed with Flowjo software (TreeStar, BD, USA). The gate strategy of Monocytes was executed as CD45+ CD36+ CD16+/−. To specifically analyse monocytes and the expression of HLA-DR and CD38 on monocytes, Cells were stained by Cytodiff reagent (CD45-PCT-J33/CD36-FTC-FA6.152/CD16-PC5-3G8/CD2-PE-39C1.5/CD294 (CRTH2)-PE-BM16/CD19-EC-J3-119) and the following antibodies: allophycocyanin (APC)-conjugated anti-human HLA-DR mAb (L234, BD Biosciences, California, USA), APC-conjugated anti-human CD38 mAb (HB-7, BD Biosciences, California, USA).

2.4. Statistical analysis

GraphPad Prism software (v.7.0a, Inc. San Diego, CA, USA) was used for statistical analysis. Data are expressed as the mean or median for continuous variables with or without normal distribution, respectively. Mann Whitney U test or unpaired test was used to compare different individuals. Multiple comparisons were made among the different groups using the Kruskal-Wallis H nonparametric test followed by Dunn’s test as the post-test. Spearman correlation test was used to assess the correlations between variables. The diagnostic value of each indicator was appraised using the receiver operation characteristic (ROC) curves. The 95% confidence interval was utilized to calculate the sensitivity, specificity and consistency, and the cut-off value was selected when the Jordan index was at its maximum. For all the tests, a two-sided P value <0.05 was considered to be significant. The statistical significance is indicated as follows: ***p < 0.0001, **p < 0.001, *p < 0.01 and ‘p < 0.05.

3. Results

3.1. Absolute number of total monocytes and subsets in COVID-19 patients

We detected the number of monocytes in COVID-19 patients with different severity and discovered that the significant increase of total monocytes in the Mild group was observed compared to HCs, and the sustained decrease of total monocytes in the Critical group was observed compared to the Mild group and the Severe group (Fig. 1A). To determine the changes of different monocyte subsets in patients with COVID-19, HematoFlow was performed to determine the absolute number of CD16− and CD16+ monocytes in COVID-19 patients with different severity. We found that CD16− monocytes in the Critical group decreased significantly as compared with the Mild and the Severe group. Furthermore, the absolute number of CD16+ monocytes in the Severe group was significantly increased compared to HCs (Fig. 1B). However, compared with the other three groups, CD16+ monocytes in the Critical group continued to increase. And the absolute number of CD16+ monocytes in COVID-19 patients with different severity all significantly increased compared to HCs (Fig. 1C).

3.2. Immune status of monocytes in COVID-19 patients

In order to investigate the antigen presentation potential of monocytes, gated as described in Fig. 2A, B, we firstly detected the expression of HLA-DR on monocytes, and the analysis showed that the expression of HLA-DR in the Critical group was significantly reduced as compared with all other groups (Fig. 2C, E). Similarly, we examined the expression of CD38 on monocytes to understand their activation status, and found that the expression of CD38 in the Critical group relatively increased as compared with all other groups (Fig. 2D, F).
3.3. Cytokine levels in COVID-19 patients

The cytokine levels, including IL-2, IL-4, IL-6, IL-10, IFN-γ and TNF-α were detected in the serum of our patient cohort. The levels of IL-6 and IL-10 showed sustained increases in the Critical group compared with the Mild group and the Severe group, and the IL-6 levels in the Severe group were higher than the Mild group (Fig. 3A, B). Furthermore, IL-2 levels were also higher in the Critical group than the Mild group (Fig. 3C). While the levels of IL-4, IFN-γ and TNF-α had trends to increase, but no statistical significance as the disease progression of COVID-19 patients (Fig. 3D–F).

3.4. The relationship between cytokine levels and monocytes by correlation analysis

We further analyzed the relationship between the elevated cytokine levels (IL-6, IL-10 and IL-2) and the number of CD16+ monocytes in patients with COVID-19. We found that the levels of IL-6 were positively correlated with the number of CD16+ monocytes (Fig. 4A). However, IL-10 and IL-2 levels were not related to the number of CD16+ monocytes (Fig. 4B, C). In addition, we found that IL-6 and IL-10 levels were negatively correlated with the expression of HLA-DR on monocytes (Fig. 4D, E). However, IL-2

Fig. 1. The absolute number of total monocytes and subsets in COVID-19 patients. (A) The absolute number of circulating total monocytes in HCs and COVID-19 patients with mild, severe and critical illness. (B) The absolute number of CD16+ monocytes in HCs and COVID-19 patients with mild, severe and critical illness. (C) The absolute number of CD16+ monocytes in HCs and COVID-19 patients with mild, severe and critical illness. Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, p < 0.0001.

Fig. 2. Immune status of monocytes in COVID-19 patients. (A, B) A full gating of flow cytometry plots of a HC and a severe COVID-19 patient. (C, D) Flow cytometry plots of HLA-DR/CD38 expression on monocytes in HCs and COVID-19 patients with mild, severe and critical illness are shown. Values in the quadrant represent the percentages of CD38+ monocytes/HLA-DR+ monocytes. MFI, Median Fluorescence Intensity. (E) The expression of HLA-DR on monocytes in HCs and COVID-19 patients with mild, severe and critical illness. (F) The expression of CD38 in HCs and COVID-19 patients with mild, severe and critical illness. The HLA-DR ratio % or CD38 ratio % represent the ratio of HLA-DR or CD38 expression on total monocytes. Calculated at the level of total monocytes. Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, p < 0.0001.
levels did not correlate with the expression of HLA-DR on monocytes (Fig. 4F). It needed to be emphasized that we removed one outlier sample because we found that the correlations were skewed by the outlier sample, which was from a critical COVID-19 patient.

3.5. Dynamic changes of monocytes in COVID-19 patients during recovery

We selected randomly several patients in each group, including 8 mild cases, 4 severe cases, and 4 critical cases to analyzed the dynamic changes of monocytes in COVID-19 patients of different severity during the recovery process. In addition, we also observed the dynamic changes of monocytes in one critical patient before death. We found that with the remission of the disease condition, the absolute number of monocytes in mild and severe patients decreased and monocytes in critical patients increased (Fig. 5A). We then analyzed the dynamic changes of monocyte subsets in COVID-19 patients. The absolute number of CD16+ monocytes increased by degrees and CD16+ monocytes gradually decreased in severe and critical patients as the disease went into remission (Fig. 5B, C). We further analyzed the dynamic changes of the expression of HLA-DR and CD38 on monocytes during recovery in COVID-19 patients, and found that HLA-DR expression on mono-
cytes increased significantly in severe and critical patients (Fig. 5D). However, the expression of CD38 on monocytes decreased in mild, severe and critical patients as the disease went into remission (Fig. 5E). In addition, we found that during the disease progression of one critical patient before death, the absolute number of monocytes and CD16⁺/CD0 monocytes were always at a low level, while CD16⁺ monocytes increased and the expression of HLA-DR on monocytes decreased, but the expression of CD38 on monocytes had no significant changes (Fig. 5A–E).

3.6. ROC curve analysis of monocytes in COVID-19 patients

We further used parameters that had different expression in disease severity to predict the critical of COVID-19 patients. Through ROC curve analysis, we found that HLA-DR⁺ monocytes (AUC = 0.961) showed the best value for predicting the incidence of critical patients with high sensitivity of 100.00% and specificity of 80.00%; followed by CD16⁻/CD0 monocytes (0.840), CD38⁺ monocytes (0.830), CD16⁺ monocytes (0.765), monocytes (0.745), with sensitivity of 100.00%, 100.00%, 77.78% and 77.78%, and specificity of 66.67%, 60.00%, 77.78% and 65.38%, respectively (Fig. 6A). The details of the data were listed in Table 1.

4. Discussion

COVID-19 is affecting the whole world, which threatening human health and life. Recent researches on immune cells in COVID-19 were mainly concerned with lymphocytes [12]. However, as an important part of innate immunity, monocytes cannot be ignored in the process of anti-SARS-CoV-2 infection. Currently,
Inflammation [7,16,17]. Therefore, we further detected CD16 because they can produce great amounts of cytokines to induce the infiltration of blood monocytes into tissues [19]. Therefore, we had reasons to speculate that the CD38 pro-inflammatory monocytes in the peripheral blood of COVID-19 patients might enter into pulmonary circulation to cause inflammation of the lungs. Monocytes cannot only migrate to infected sites and directly engulf pathogens [6], but also present microbial antigens to T cells to initiate and regulate immune responses. The expression of HLA-DR on monocytes plays an essential role in presenting antigens to adaptive immune cells [7,8]. And the expression of HLA-DR is negatively correlated with the severity of immune dysfunction [20]. The reduced expression of HLA-DR on monocytes has been widely accepted as a reliable indicator of immunosuppression in the ICU patients [21]. To further understand the immune status of monocytes in COVID-19 patients, we detected the antigen presentation potential of monocytes, and found that the expression of HLA-DR on circulating monocytes in critical patients was significantly decreased compared to HCs, mild and severe patients. The results indicated that the antigen presentation potential of monocytes in COVID-19 patients with critical disease might be impaired, and monocytes might not effectively present the antigens to T cells and regulate the immune response against SARS-CoV-2. In recent studies, researchers divided COVID-19 patients into Mild and Severe groups, and also found that COVID-19 patients with severe SARS-CoV-2 symptoms had down-regulated HLA-DR levels of monocytes [22,23].

We further detected cytokine levels in the serum of COVID-19 patients and found that IL-6, IL-10 and IL-2 levels increased significantly in the critical patients. Through correlation analysis, we further found that IL-6 were positively correlated with the number of CD16+ monocytes. A previous study also found that great amounts of IL-6 could be detected in CD16+ pro-inflammatory monocytes, especially in ICU patients with COVID-19 [9]. These results suggested that in critical patients of COVID-19, increased activated CD16+ pro-inflammatory monocytes might be related to the production of great amounts of cytokines, especially IL-6, which could induce excessive inflammation and lead to immune disorders. On the other hand, it reminded us that IL-6 inhibition might mitigate severe inflammation in COVID-19 patients. A study had confirmed our conjecture that the use of IL-6 blockers can alleviate the inflammatory responses of COVID-19 patients [24]. Besides, we found that the IL-6 and IL-10 levels were negatively correlated with the expression of HLA-DR on monocytes in COVID-19 patients. Ohno Y. et al found that IL-6 could downregulate HLA-DR expression [25]. Therefore, we speculated that excessively secreted IL-6 and IL-10 in critical patients with COVID-19 might inhibit HLA-DR expression on monocytes, which could lead to impaired antigen presentation potential of monocytes. It was consistent with the study of Evangelos J. et al., which found that COVID-19 patient plasma strongly inhibited the expression of HLA-DR on monocytes, and it was partially restored by the IL-6 blocker Tocilizumab [26].

In addition, we analyzed the dynamic changes of monocytes during recovery in COVID-19 patients with different severity. We found that with the remission of the disease condition, the number of total monocytes and CD16+ monocytes increased gradually, while CD16+ monocytes decreased in critical patients. Additionally, we also found that during recovery in COVID-19 patients, the expression of HLA-DR on monocytes increased, while CD38 on

### Table 1

ROC curve parameters for predicting the incidence of critical patients.

| Parameters  | AUC     | P        | 95% CI     | Cut-off value | Jordan index | Sensitivity | Specificity |
|------------|---------|----------|------------|---------------|--------------|-------------|-------------|
| DR + Mo    | 0.961   | <0.0001  | 0.899–1.000| >81.55        | 0.800        | 100.00%     | 80.00%      |
| CD16-Mo    | 0.840   | 0.0047   | 0.690–0.989| >8.639        | 0.667        | 100.00%     | 66.67%      |
| CD38 + Mo  | 0.830   | 0.0050   | 0.682–0.979| >98.50        | 0.600        | 100.00%     | 60.00%      |
| CD16 + Mo  | 0.765   | 0.0270   | 0.534–0.997| >0.83         | 0.556        | 77.78%      | 77.78%      |
| Mo         | 0.745   | 0.0199   | 0.539–0.950| <405.00       | 0.432        | 77.78%      | 65.38%      |

DR + Mo refers to the ability of HLA-DR+ monocytes for predicting the incidence of critical patients; Mo, monocytes; AUC, area under the curve; 95% CI, 95% confidence interval.
monocytes exhibited a downward trend. These results might suggest that in COVID-19 patients, the antigen presentation potential of monocytes restoratively enhanced and activation was weakened with the remission of the disease condition. Besides, we found that in the disease progression of one critical patient before death, the number of total monocytes was always at a low level and the expression of HLA-DR on monocytes decreased significantly, while CD16+ monocytes increased significantly, which was the opposite of a well-recovered COVID-19 patient. As the condition of COVID-19 patients deteriorated, the number of monocytes was reduced, their immune function might be suppressed and CD16+ monocytes might play pro-inflammatory function, which might mediate excessive inflammation. Besides, we found that HLA-DR+ monocytes might serve as a meaningful assisted indicator to help predict the incidence of critical patients with COVID-19, which could be much valuable for patient treatment.

In summary, decline in number and HLA-DR expression of monocytes might lead to decreased antigen presentation potential and thus immunosuppression in critical patients with COVID-19 to some extent. However, increased CD16+ pro-inflammatory monocytes might be related to the production of large amounts of cytokines, especially of IL-6, which might mediate hyperinflammation and inhibit antigen presentation potential of monocytes. Besides, HLA-DR+ monocytes might serve as a meaningful assisted indicator to help predict the incidence of critical patients with COVID-19. These findings might provide a new perspective for the diagnosis and treatment of critical patients with COVID-19.

Funding
This work was supported by the Natural Science Foundation of Zhejiang Province of China (grant number LY16H200004).

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
[1] N. Zhu, D. Zhang, W. Wang, et al., A novel coronavirus from patients with pneumonia in Wuhan, China, 2019, N. Engl. J. Med. 382 (8) (2020) 727–733, https://doi.org/10.1056/NEJMa2001017.
[2] World Health Organization (WHO), Coronavirus Disease (COVID-19) Outbreak Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed 15 October 2020).
[3] D. Wang, B. Hu, C. Hu, et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China, JAMA 323 (11) (2020) 1061–1069, https://doi.org/10.1001/jama.2020.1585 (published online ahead of print, 2020 Feb 7).
[4] C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5 (published correction appears in Lancet. 2020 Jan 30).
[5] B.P. Kaur, E. Secord, Innate immunity, Pediatr. Clin. North Am. 66 (5) (2019) 905–911, https://doi.org/10.1016/j.pcl.2019.06.011.
[6] N.V. Serbina, T. Jia, T.M. Hohl, E.G. Palmer, Monocyte-mediated defense against microbial pathogens, Annu. Rev. Immunol. 26 (2008) 421–452, https://doi.org/10.1146/annurev.immunol.26.021607.090326.
[7] J. Yang, L. Zhang, C. Yu, X.-F. Yang, H. Wang, Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases, Biomark. Res. 2 (1) (2014) 1, https://doi.org/10.1186/2045-7711-2-1.
[8] W.C. Cheadle, The human leukocyte antigens and their relationship to infection, Am. J. Surg. 165 (2A Suppl) (1993) 755–815, https://doi.org/10.1016/S0002-9610(93)81120-3.
[9] B. Xu, X. Hu, H. Wei, Why tocilizumab could be an effective treatment for severe COVID-19?, J. Transl. Med. 18 (1) (2020) 164, https://doi.org/10.1186/s12967-020-02339-3, Published 2020 Apr 14.
[10] C. Qin, L. Zhou, Z. Hu, et al., Disregulation of immune response in patients with COVID-19 in Wuhan, China [published online ahead of print, 2020 Mar 12], Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa248 (ciaa248 published online ahead of print, 2020 Mar 12).
[11] National Health Commission of China, New coronavirus Pneumonia Prevention and Control Program, Available at: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7d4fe4ce80d8c75912e1b989.shtm?spm=C7354489212.12059511941341.0.0, (accessed 5 July 2020).
[12] Y. Jiang, X. Wei, J. Guan, et al., COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytokytic potential, Clin. Immunol. 218 (2020) 108516, https://doi.org/10.1016/j кллиму.2020.108516.
[13] B. Peruzzi, S. Bencini, M. Capone, et al., Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection, Immunology (2020), https://doi.org/10.1111/imn.13254.
[14] H.W. Ziegler-Heitbrock, B. Passlick, D. Flieger, The monoclonal antimonocyte antibody Mø4 stains B lymphocytes and two distinct monocyte subsets in human peripheral blood, Hybridoma 7 (6) (1988) 521–527, https://doi.org/10.1089/hib.1988.7.521.
[15] B. Passlick, D. Flieger, H.W. Ziegler-Heitbrock, Identification and characterization of a novel monocyte subpopulation in human peripheral blood, Blood 74 (7) (1989) 2527–2534.
[16] K.L. Wong, J.J. Tai, W.C. Wong, et al., Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets, Blood. 118 (5) (2011) e16–e31, https://doi.org/10.1182/blood-2010-12-326355.
[17] L. Ziegler-Heitbrock, The CD14+ CD16+ blood monocytes: their role in infection and inflammation, J. Leukoc. Biol. 81 (3) (2007) 584–592, https://doi.org/10.1189/jlb.0806510.
[18] S.A. Amici, N.A. Young, J. Narvaez-Miranda, et al., CD38 is robustly induced in human macrophages and monocytes in inflammatory conditions, Front. Immunol. 9 (2018) 1593, https://doi.org/10.3389/fimmu.2018.01593, Published 2018 Jul 10.
[19] F. Malavasi, S. Deaglio, A. Fanaro, et al., Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology, Physiol. Rev. 88 (3) (2008) 841–886, https://doi.org/10.1152/physrev.00035.2007.
[20] Y. Zhuang, H. Peng, Y. Chen, et al., Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis, Front. Biosci. (Landmark Ed.) 22 (2017) 1344–1354, https://doi.org/10.2741/4547, Published 2017 Mar 1.
[21] A. Gouel-Chéron, B. Allaouchiche, C. Guignant, et al., Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma, PLoS One 7 (3) (2012), https://doi.org/10.1371/journal.pone.0033095.
[22] A. Silvin, N. Chapuis, G. Dunsmore, et al., Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19, Cell 182 (6) (2020) 1401–1418.e18, https://doi.org/10.1016/j.cell.2020.08.002.
[23] A. Gatti, D. Radizzani, P. Viganò, et al., Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection, Cytometry A 97 (9) (2020) 887–890, https://doi.org/10.1002/cyto.a.24188.
[24] X. Xu, M. Han, T. Li, et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc. Natl. Acad. Sci. U.S.A. 117 (20) (2020) 10970–10975, https://doi.org/10.1073/pnas.2005691117.
[25] Y. Ohno, H. Kitamura, N. Takahashi, et al., IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells, Cancer Immunol. Immunother. 65 (2) (2016) 193–204, https://doi.org/10.1007/s00262-015-1797-4.
[26] E.J. Giamarellos-Bourboulis, M.G. Netea, N. Rovina, et al., Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe 27 (6) (2020) 992–1000.e3, https://doi.org/10.1016/j.chom.2020.04.009.